TY  - JOUR
A1  - Heller, Martin
A1  - Henrici, Clara Blanca
A1  - Büttner, Judith
A1  - Leube, Sebastian
A1  - Treske, Isabelle
A1  - Pospischil, Petra
A1  - Doll, Michael
A1  - Schanz, Ilka
A1  - Hallier, Agnes
A1  - Herrmann, Eva
A1  - Schmidt, Michael
A1  - Sarrazin, Christoph
T1  - SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
T2  - International journal of infectious diseases
N2  - Objectives In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed.
Methods: Patients in the intervention groups received bamlanivimab or casirivimab/imdevimab. Patients without treatment served as control. Outcomes were assessed by clinical symptoms and change in log viral load from baseline based on the cycle threshold over a period of 18 days.
Results: Median log viral load decline was higher in both intervention groups after 3 and 6 days compared to control. However, at later time points, the decline of the viral load was more distinct in the control group. Mild symptoms of COVID-19 were observed in 6.3% of the intervention groups and in no patient of the control. No patients treated with bamlanivimab, 18.8% treated with casirivimab/imdevimab, and 14.2% in the control group developed moderate symptoms. Severe symptoms were recorded only in the control group (14.2%), including one related death.
Conclusion: Treatment with monoclonal SARS-CoV-2 antibodies seems to accelerate decline of virus loads, especially in the first 6 days after administration, compared to control. This may be associated with a reduced likeliness of a severe course of COVID-19.
KW  - COVID-19
KW  - Bamlanivimab
KW  - Casirivimab
KW  - Imdevimab
KW  - Antibody therapy
KW  - Viral load
Y1  - 2023
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/78857
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-788570
SN  - 1201-9712
VL  - 129
SP  - 260
EP  - 265
PB  - Elsevier
CY  - Amsterdam
ER  -